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comparison with the general population. If the patient survives this stage, they then progress into the final stage of the model which reflects a return to the normal patient life expectancy. The time horizon of the model was the patients' lifetime.
Outcomes assessed in the review
The following main input parameters were identified from the literature and used in the model: 28-day mortality for patients with severe sepsis and for patients with severe sepsis and multiple organ dysfunction (MOD), and the equivalent relative risk (RR); the additional risk of a serious bleeding event during the 28-day survival period; the risk of death in years 1, 2, 3 and 4 following the 28-day survival period; and the health state value for survivors of severe sepsis.
Study designs and other criteria for inclusion in the review
The inclusion criteria for the review were not reported in this paper. However, the authors reported that the effectiveness data were mainly derived from a large randomised controlled trial (the PROWESS study). Data on the baseline population were derived from the ICNARC.
Sources searched to identify primary studies
The sources were not reported in this paper (see Green et al. 2005 for relevant details).
Criteria used to ensure the validity of primary studies
Not reported in this paper (see Green et al. 2005 for relevant details).
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
The authors mainly reported 5 studies as sources of effectiveness evidence. However, it was unclear how many studies were actually reviewed.
Methods of combining primary studies
The methods used were not reported in this paper (see Green et al. 2005 for relevant details).
Investigation of differences between primary studies
Results of the review
Twenty-eight-day mortality was 41.5% (40.8% to 42.3%) for patients with severe sepsis and 46.2% (45.3% to 47.1%) for patients with severe sepsis and MOD. The RR was 0.79 (0.68 to 0.92) for patients with severe sepsis and 0.78 (0.66 to 0.93) for patients with severe sepsis and MOD.
The additional risk of a serious bleeding event during the 28-day survival period was 1.5%.
The risk of death following the 28-day survival period was 19.4% in year 1, 5.68% in year 2, 4.75% in year 3 and 3.91% in year 4.
All other parameters used in the model (including health state values and resource use) were reported in full, but are too numerous to be reported here.
Measure of benefits used in the economic analysis
The measures of benefit used were the life-years gained (LYG) and health utility (quality-adjusted life-years, QALYs). The LYG were directly derived from the model using life expectancy and risk of death estimates from the literature. Given that health state values for survivors of severe sepsis were not available in the literature, the authors used quality of life data for a sample of patients with acute respiratory distress syndrome (at 12 months), which had been derived from a published study.
Direct costs
The following health service costs were included in the analysis: the cost of drotrecogin alfa (activated); the mean cost per patient (excluding Value Added Tax, VAT) for severe sepsis and severe sepsis with MOD; the mean cost of a serious bleed; the cost per day in the intensive care unit; the cost per day in another hospital ward; hospitalisation costs for severe sepsis survivors and non-survivors; hospitalisation costs for survivors and non-survivors with severe sepsis and MOD; the long-term mean annual NHS costs for patients aged 16 to 44 years, 45 to 64 years, and above 65 years; and a mean estimate of long-term NHS cost (excluding initial intervention and acute care).
The costs and the quantities of resources used were reported separately. The quantities of resources used were based on ICNARC unpublished data, while costs estimates were derived from published official sources. Since the costs were incurred over more than 2 years (patients' lifetime), discounting was appropriately conducted. It appears that all costs were reported for the price year 2002.
Statistical analysis of costs
The costs were treated deterministically.
Indirect Costs
In line with the perspective adopted, the indirect costs were not included in the analysis.
Currency

UK pounds sterling ().
Sensitivity analysis
The authors conducted various one-way sensitivity analyses to test the effect of variability in the data on the robustness
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an adjustment factor of life expectancy for survivors of severe sepsis of 51%, as opposed to 70% used in the baseline analysis;
long-term patient costs adjusted using a factor 0.51; long-term costs per patient per year higher than 10,000 in year 1;
long-term costs per patient per year higher than 20,000 in year 1; no long-term costs;
QALY weight/utility of 0.69; cost of drotrecogin alfa including VAT;
RRs of 0.70, 0.75, 0.85, 0.90 and 0.95; probability of a serious bleeding event of 15%.
In addition, three multi-way sensitivity analyses were also conducted:
QALY weight of 0.69 and exclusion of long-term costs;
long-term costs per patient of 20,000 in year 1, with base-case values after that, and life expectancy adjusted to 0.51 of the population norm;
long-term costs per patient of 20,000 in year 1, with base-case values after that, and life expectancy adjusted to 0.51, plus baseline all-cause mortality risk of 33.9% for patients with severe sepsis and MOD and 31.3% for patients with severe sepsis.
Assumptions used in the sensitivity analyses were mainly derived from published literature. In addition, a probabilistic Monte Carlo simulation was undertaken to address parameter uncertainty. Details of parameter distributions were not presented.
Estimated benefits used in the economic analysis
In the base-case analysis, an incremental analysis was conducted. When drotrecogin alfa (activated) plus conventional treatment was compared with conventional treatment alone it resulted in an incremental life-years gain (mean) of 1.144 (standard deviation, SD=0.343) and an incremental QALY gain (mean) of 0.686 (SD=0.208) for patients with severe sepsis. For patients with severe sepsis and MOD, the incremental life-year gain (mean) was 1.351 (SD=0.430) and the incremental QALY gain (mean) was 0.810 (SD=0.258).
Cost results
An incremental cost analysis was performed. When drotrecogin alfa (activated) plus conventional treatment was compared with conventional treatment alone, the incremental cost was 6,288 (SD=593) for patients with severe sepsis and 6,661 (SD=772) for patients with severe sepsis and MOD.
Synthesis of costs and benefits
An incremental cost-effectiveness analysis was performed. When drotrecogin alfa (activated) plus conventional treatment was compared with conventional treatment alone, the cost per additional LYG was 5,495 for patients with severe sepsis and 4,931 for patients with severe sepsis and MOD. The cost per QALY was 9,161 for patients with severe sepsis and 8,228 patients with severe sepsis and MOD.
